Research article · 19 Aug 2025
Conference abstractPublished 11 Aug 2015
Mechanistic study of NVP-CGM097: A potent, selective and species specific inhibitor of p53-Mdm2
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
An effective strategy to restore p53 activity in cancer cells containing wild type p53 is to inhibit the Mdm2-p53 proteinprotein interaction (PPI). NVP-CGM097 is a novel PPI inhibitor under evaluation in a Phase I clinical trial. It binds to the p53 binding-site of the Mdm2 protein, disrupting the interaction between both proteins, leading to an activation of the p53 pathway. The main biophysical and biochemical inhibitory characteristics of NVP-CGM097 are presented here. These include affinity constants for Mdm2 & Mdm4, and the binding kinetics of NVP-CGM097. Moreover, biochemical studies have revealed the species specificity of NVP-CGM097 with human Mdm2 being inhibited more strongly than the dog, mouse or rat forms of the protein. This was confirmed in cellular assays where NVP-CGM097 treatment resulted in induction of p53 target gene expression (p21, PUMA and Mdm2) only in human, but not in dog, mouse or rat cell lines.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Drug Designing: Open Access.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalDrug Designing: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Marie Therese Valat”
